Pharmacokinetics of prulifloxacin in hemodialysis patients

DOI Web Site 9 References
  • Ichimaru Naotsugu
    Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine
  • Kojima Yasuyuki
    Department of Urology, Inoue Hospital
  • Tsujimoto Yoshihiro
    Department of Internal Medicine, Inoue Hospital
  • Okumi Masayoshi
    Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine
  • Yazawa Koji
    Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine
  • Nonomura Norio
    Department of Specific Organ Regulation (Urology), Osaka University Graduate School of Medicine
  • Kaimori Junya
    Department of Transplantation of Advanced Medical Technology, Osaka University Graduate School of Medicine
  • Takahara Shirou
    Department of Transplantation of Advanced Medical Technology, Osaka University Graduate School of Medicine

Bibliographic Information

Other Title
  • 血液透析患者におけるプルリフロキサシン薬物動態の検討
  • ケツエキ トウセキ カンジャ ニ オケル プルリフロキサシン ヤクブツ ドウタイ ノ ケントウ

Search this article

Abstract

[Objective] To clarify the pharmacokinetic profile of prulifloxacin (PUFX) in patients undergoing hemodialysis (HD). [Methods] The plasma concentration of ulifloxacin (UFX), the active metabolite of PUFX, was measured in 8 HD patients after single or multiple once-daily oral administration of prulifloxacin (264.2mg). HD was performed with a blood flow of 180~290mL/min from 2 to 6h after dosing following a single administration and on alternate days for patients receiving successive administrations. [Results] In single administration, the biological half life in blood and the area under the curve for UFX were 15.4±4.5hr and 12.9±6.7μg•hr/mL, respectively. In daily administration, the plasma concentration of UFX on day3 was higher than that on day1 pre HD and post HD, but there was no significant difference (pre HD, p=0.2180 ; post HD, p=0.1635). There were no apparent side effects during the study period. [Conclusion] The pharmacokinetic profile of PUFX suggested that the appropriate dosage of PUFX was 132.1mg once a day and the HD procedure was performed from 4 to 6hr after administration of PUFX in HD patients.

Journal

References(9)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top